Japan faces one of the world’s most acute ageing trends—over 29% of the population is 65 or older—driving sustained demand for healthcare and elderly care. This target is a premium regenerative medicine facility in Tokyo focused on precision check-ups and stem cell therapy; market valuation exceeds ¥3bn, with leading regenerative technology and a stable high-end client base.
HaoHao is building an integrated “finance + IT data + healthcare” ecosystem. Post-investment plans combine consumer finance and digital healthcare to create a cross-border medical tourism platform. We are experienced in Japanese medical corporation and MS corporation structures, helping investors maximise operational involvement and returns within a compliant framework.
Premium healthcare demand — Precision check-ups and stem cell therapy have growing demand in Japan and cross-border medical tourism.
Consumer finance — Leveraging Type 1 licence resources to offer instalment and payment solutions for premium medical clients.
Digital healthcare — Doni AI and medical IT to improve EMR, telemedicine and CRM efficiency.
